Your Messages Inbox
Your Article Summary
See Latest ArticlesNew data illustrate novel mechanism of action of laquinimod, an oral compound for the treatment of multiple sclerosis
Active Biotech, 04/29/09
Teva Pharmaceutical Industries Ltd. and Active Biotech announced results from several new clinical and preclinical studies providing further insight on the immunomodulatory mechanism of action of laquinimod, a novel oral once-daily compound being developed for the treatment of relapsing-remitting multiple sclerosis. Four sets of data being presented at the 61st Annual American Academy of Neurology Meeting in Seattle stand to increase the understanding of how laquinimod may reduce multiple sclerosis activity and affect mechanisms related to disease pathology.
Today in Biotechnology...keeping you current
Receive free subspecialty "5-minute updates" via email
Sanofi-aventis and U.S Biotechnology company Alopexx enter into a collaboration agreement for a novel human monoclonal antibody targeting infectious diseases
Sanofi-aventis, 12/11/09
Quality by Design for Biotechnology Products—Part 2
BioPharm, 12/09/09
Amylin Pharmaceuticals to Present at the 2009 Deutsche Bank Biotech Boston Confab
Amylin Pharmaceuticals, 12/09/09
Article Search
Sponsor